Panbela Therapeutics, Inc. (NASDAQ:PBLA) Q4 2022 Earnings Call Transcript

Jennifer Simpson: Yeah. So if you — that’s an interesting question actually, because when you — depending on who you talk to, right, clinicians, regulatory bodies. I think the kind of base case would be at least a three-month improvement in survival. When you look at the approval of gem and Abraxane over gemcitabine alone, you went from roughly 6.7 to about 8.5. We certainly believe that we would like to see a more meaningful benefit of at least three months. This is an area that really is in need of options, but we are anticipating to see at least a three-month benefit, obviously, higher would be great.

Jonathan Aschoff: Yeah. Thank you very much.

Jennifer Simpson: Certainly.

Operator: Thank you. That concludes our Q&A session. Everyone this concludes today’s event. You may disconnect at this time and have a wonderful day. Thank you for your participation.